Novel vaccine development against COVID-19

We have previously developed a DNA based vaccine platform, and demonstrated that steering of antigens to selected receptors on antigen presenting cells enhances vaccine efficacy. Further, we can modulate the formation of immune responses to different types by careful selection of the receptors against which the antigen is steered. As an example, we have demonstrated, in both mice and larger animals, that directing antigen to HLA class II molecules is particularly relevant for induction of neutralizing antibodies, whereas steering of antigen to chemokine receptors promotes stronger formation of cellular immunity. At present, we are inserting various forms of the SARS-CoV-2 Spike protein into our DNA vaccines, and are interested in collaborations that can further vaccine advancements against COVID-19.
Bjarne Bogen's research group:
Cellular and Molecular Immunology
Gunnveig Grødeland's research group:
Influenza and Adaptive Immunity
Page visits: 343